Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is well-positioned for long-term success with a growing portfolio of tests, strong customer and payer relationships, and expansion into new markets. Their recent FDA approvals and partnerships with organizations like NCCN and ACS bode well for potential revenue growth. With plans to invest in their Shield screening business, GH has the potential to become a multi-billion dollar company.

Bears say

Guardant Health is facing multiple challenges in the highly competitive and uncertain market of liquid-based cancer tests. While the company has delivered a few positive catalysts in 2026, there remain significant uncertainties and risks in the near term, particularly with regards to Medicare coverage decisions for its Reveal test. Additionally, the company has a high cash burn rate and a smaller market for its blood-based cancer screening test than initially expected. There are also concerns about valuation and competition, and the company may need to raise additional capital in the future. Therefore, the negative outlook on Guardant Health's stock is justified.

GH has been analyzed by 23 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 23 analysts, GH has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $187.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $187.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.